Report

Roche suffers trial setback

While the safety profile was in line with previous lampalizumab trials, the drug did not reduce mean change in GA lesion area compared with sham treatment. The results have placed extra significance on the results of Roche’s second phase III study, which will be released this month.{{quote-A:R-W:450-Q:The results have placed extra significance on the results of Roche’s second phase III study}}Roche shares dropped nearly 2% following the announcent, compounding the company’s relative underperformance in the year to date compared with the overall gains made by the industry.“While this result is disappointing, we will continue to evaluate results from Spectri to get a clearer understanding of the data as we await the results of our second phase III study, Chroma,” Roche’s chief medical officer Dr Sandra Horning said.Both Spectri and Chroma are identically-designed, double-masked, global studies evaluating the efficacy and safety of a 10 mg dose of lampalizumab administered every 4–6 weeks by intravitreal injection, versus sham injections in patients with GA due to age-related macular degeneration.

Send this to a friend